ClinicalTrials.gg
CompletedNCT04875676VXA-NVV-105Updated May 22, 2024Results posted

Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines

A Phase 1/2 interventional study of VXA-G1.1-NN in Norovirus Infections, sponsored by Vaxart. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Vaxart · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Caliciviridae Infections with a site in United States — none open to participants now, none under way, none of them phase 3. Caliciviridae Infections · United States.

Enrollment
8th of 11
30 · median 60
Started
2021
with 2 others
Phase 1/2
3 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
7 of 11
Vaxart

Among the 11 studies in Caliciviridae Infections with a site in United States, this one is the 8th largest by enrollment, is one of 3 that started in 2021, is one of 3 in phase 1/2, and was the 6th registered.

Caliciviridae Infections

20 studies on the registry are indexed under Caliciviridae Infections; 2 are open to participants now.

Browse Caliciviridae Infections studies →

Open to participants now

None of the 11 studies in Caliciviridae Infections with a site in United States is open now. The open studies under Caliciviridae Infections, anywhere →

Who these studies take

Of the 2 Caliciviridae Infections studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Caliciviridae Infections with a site in United States as a file.
02

Study summary

To evaluate the immunogenicity of VXA-G1.1-NN with repeat-dose administration at Day 1 and varying boost schedules (Week 4, 8 or 12 post initial dose) in healthy adults aged 18-55, inclusive, and to assess the safety and tolerability of VXA- G1.1-NN with repeat-dose administration at varying boost schedules (Week 4, 8 or 12) in healthy adults aged 18-55, inclusive

03

Conditions studied

  • Norovirus Infections
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • To be eligible for this study, participants must meet all the following:

Age

  1. 18 to 55 years old inclusive at the time of signing the Form (ICF).

    Type of Participants

  2. General good health, without significant uncontrolled medical illness, based on medical history, physical examination, vital signs, and clinical laboratories (CBC, chemistry, and urinalysis) as determined by the investigator in consultation with the Research Monitor and Sponsor
  3. (BMI) between 17 and 35 kg/m2 at screening
  4. Available for all planned visits and phone calls, and willing to complete all protocol- defined procedures and assessments (including ability and willingness to swallow multiple small enteric-coated tablets per study dose).

    Gender and Reproductive Considerations

  5. Male or female participants use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    a. Female participants must provide a negative pregnancy test at each required visit and fulfill one of the following criteria:

    • At least 1 year (defined as amenorrhea for ≥12 consecutive months prior to Screening without an alternative medical cause).
    • Women under 60 years will need to verify post-menopausal status via a follicle-stimulating hormone (FSH) test if another option to prevent potential pregnancy will not be utilized for 30 days prior to baseline vaccination and until 60 days after the last vaccination.
    • Surgically sterile
    • Use of oral, implantable, transdermal or injectable contraceptives for 30 days prior to initial vaccination and until 60 days after the last vaccination. The form of contraception must be approved by the Investigator
    • A reliable form of contraception must be approved by the Investigator (e.g., double barrier method, Depo-Provera, intrauterine device, Norplant, oral contraceptives, contraceptive patches).
    • Not be sexually active (abstinent) or be in a relationship with partner who is sterile (must be discussed with site staff and documented).

    Informed Consent

  6. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • The participants must be excluded from participating in the study if they meet any of the following:

Medical Conditions

  1. Presence of significant uncontrolled medical or psychiatric illness (acute or chronic) including institution of new medical/surgical treatment or significant dose alteration for uncontrolled symptoms or drug toxicity within 3 months of screening and reconfirmed at baseline
  2. Cancer, or received treatment for cancer, within past 3 years (excluding basal cell carcinoma or squamous cell carcinoma)
  3. Presence of or medical condition possibly associated with impaired immune responsiveness, including diabetes mellitus 1 and 2
  4. History of irritable bowel disease or other inflammatory digestive or gastrointestinal condition that could affect the distribution/safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine.

    Such conditions may include but are not limited to:

    1. Esophageal Motility Disorder
    2. Malabsorption
    3. Pancreaticobiliary disorders
    4. Irritable bowel syndrome
    5. Inflammatory Bowel Disease
    6. Surgical Resection
    7. GERD
    8. Hiatal Hernia
    9. Peptic Ulcer (History of cholecystectomy is not exclusionary)
  5. History of any form of angioedema
  6. History of serious reactions to any vaccination such as anaphylaxis, respiratory problems, hives or abdominal pain
  7. Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make blood draws problematic
  8. Any condition that resulted in the absence or removal of the spleen
  9. Acute disease within 72 hours prior to vaccination defined as the presence of a moderate or severe illness (as determined by the Investigator through medical history and physical exam). (Assessment may be repeated during screening period.)
  10. Presence of a fever ≥ 38oC measured orally at baseline (Assessment may be repeated during screening period)
  11. Any significant hospitalization within the last year which in the opinion of the Investigator or Sponsor could interfere with study participation.
  12. Any other condition that in the clinical judgment of the investigator would jeopardize the safety or rights of a participant taking in the study, would render the participant unable to comply with the protocol or would interfere with the evaluation of the study endpoints Diagnostic Assessments
  13. Positive (HIV), surface antigen (HBsAg) or virus (HCV) tests at the screening visit
  14. Positive urine drug screen for drugs of abuse at screening
  15. Positive breath or urine alcohol test at screening and baseline Prior/Concurrent Therapy
  16. Receipt of a licensed vaccine within 14 days prior to baseline vaccination or planned administration during the study active period (4 weeks post each study vaccination).
  17. Use of antibiotics, proton pump inhibitors, H2 blockers or antacids within 7 days prior to study drug administration or planned use during the active study period
  18. Use of medications known to affect the immune function (e.g., systemic and others) within 2 weeks before study drug administration or planned use during the active study period
  19. Daily use of nonsteroidal anti-inflammatory drugs within 7 days prior to study drug administration or planned use during the active study period
  20. Administration of any vaccine, drug or device within 8 weeks preceding study drug administration (Day 1), or planned use within the duration of the study Other Exclusions
  21. Donation or use of blood or blood products within 30 days prior to study drug administration or planned donation during the active study period
  22. History of drug, alcohol or chemical abuse within 1 year of screening
  23. History of or allergic reaction to any component of the investigational vaccine, including but not limited to fish gelatin
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Cohort 1 (4-week boost vaccination)

    (4-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU ± 0.5 log at Day 1 and Week 4

    Biological: VXA-G1.1-NN

  • Active comparator
    Cohort 2 (8-week boost vaccination)

    (8-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU± 0.5 log at Day 1 and Week 8

    Biological: VXA-G1.1-NN

  • Active comparator
    Cohort 3 (12-week boost vaccination)

    (12-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU± 0.5 log at Day 1 and Week 12

    Biological: VXA-G1.1-NN

Interventions

  • BiologicalVXA-G1.1-NN

    Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with double-stranded RNA Adjuvant

06

What researchers measure

Primary outcomes

  1. Viral-capsid Protein 1 (VP1)-Specific Antibody Secreting Cells (ASC) by Enzyme-linked Immunospot (ELISpot) Assay

    Comparison of VPI specific immunoglobin A (IgA) ASC levels between the 3 study cohorts by enzyme-linked immunospot (ELISpot) assay

    Time frame: Day 1 (Initial Vaccination) through Day 8 post boost (Second Vaccination)

  2. Norovirus G1.1 Histo-blood Group Antigen (HBGA) Blocking Antibodies (BT50) Assay

    Comparison of subjects with a ≥2-, 3- or 4-fold increase over baseline titer of GI.1 histo-blood group antigen (HBGA) blocking antibodies (BT50) levels between the 3 study cohorts.

    Time frame: Day 1 (Initial Vaccination) through Day 29 post boost (Second Vaccination)

  3. VP1 Serum Immunoglobin G (IgG) by Mesoscale Discovery (MSD) Assay

    Comparison of VPI specific immunoglobin A (IgA) ASC levels by Mesoscale Discovery (MSD) assay between the 3 study cohorts

    Time frame: Day 1 (Initial Vaccination) through Day 29 post boost (Second Vaccination)

  4. Norovirus G1.1 Histo-blood Group Antigen (HBGA) Blocking Antibodies (BT50) Assay

    Comparison of GI.1 histo-blood group antigen (HBGA) blocking antibodies (BT50) levels between the 3 study cohorts

    Time frame: Day 1 (Initial Vaccination) through Day 29 post boost (Second Vaccination)

Secondary outcomes

  1. Solicited Symptoms of Reactogenicity

    Comparison of frequency, duration, and severity of solicited symptom events in participants

    Time frame: Day 1 (Vaccination) to Day 8 post each vaccination

Other outcomes

  1. Unsolicited Adverse Events (AEs)

    Comparison of the frequency, duration, and severity of unsolicited AEs and serious AEs (SAEs) including AEs of Special Interest (AESIs) and new onsets of chronic illness (NOCIs) in participants

    Time frame: Day 1 (Vaccine) through 28 days following boost (Second Vaccination)

  2. Long-term Safety

    Frequency, duration, and severity of all SAEs, AESIs and NOCIs through 6 months after last vaccination.

    Time frame: Day 1 (Vaccine) through 6 months following boost (Second Vaccination)

07

Results

Posted May 22, 2024

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 (4-week Boost Vaccination)Cohort 2 (8-week Boost Vaccination)Cohort 3 (12-week Boost Vaccination)
Started101010
Completed91010
Not completed100
Withdrew: Lost to follow-up100

Outcome measures

PrimaryViral-capsid Protein 1 (VP1)-Specific Antibody Secreting Cells (ASC) by Enzyme-linked Immunospot (ELISpot) Assay

Comparison of VPI specific immunoglobin A (IgA) ASC levels between the 3 study cohorts by enzyme-linked immunospot (ELISpot) assay

Time frame:
Day 1 (Initial Vaccination) through Day 8 post boost (Second Vaccination)
Reported as:
Mean · Spot Forming Units per 10^6 PBMC
Viral-capsid Protein 1 (VP1)-Specific Antibody Secreting Cells (ASC) by Enzyme-linked Immunospot (ELISpot) Assay
Spot Forming Units per 10^6 PBMCCohort 1 (4-week Boost Vaccination)Cohort 2 (8-week Boost Vaccination)Cohort 3 (12-week Boost Vaccination)
First Dose1.3 (-0.4 to 3.0)0.5 (-0.4 to 1.3)0.3 (-0.2 to 0.8)
7-Days post First Dose127.6 (23.8 to 231.4)214.3 (15.8 to 412.9)327.5 (-106.4 to 761.4)
Second Dose2 (0.1 to 4.0)2.1 (-1.1 to 5.2)2.3 (-0.3 to 4.8)
7-Days post Second Dose25.5 (-6.2 to 57.2)68.8 (-29.4 to 167.0)132.1 (-16.1 to 280.4)
PrimaryNorovirus G1.1 Histo-blood Group Antigen (HBGA) Blocking Antibodies (BT50) Assay

Comparison of subjects with a ≥2-, 3- or 4-fold increase over baseline titer of GI.1 histo-blood group antigen (HBGA) blocking antibodies (BT50) levels between the 3 study cohorts.

Time frame:
Day 1 (Initial Vaccination) through Day 29 post boost (Second Vaccination)
Reported as:
Geometric mean · 10^6 AU/mL
Norovirus G1.1 Histo-blood Group Antigen (HBGA) Blocking Antibodies (BT50) Assay
10^6 AU/mLCohort 1 (4-week Boost Vaccination)Cohort 2 (8-week Boost Vaccination)Cohort 3 (12-week Boost Vaccination)
Day of First Dose: GMC (geometric mean concentration)29.9 (17.0 to 52.6)27.9 (12.8 to 60.9)21.1 (12.0 to 37.1)
28-Days post First Dose: GMC (geometric mean concentration)52.7 (28.8 to 96.2)69.5 (23.2 to 208.4)54.9 (18.7 to 161.2)
28-Days post Second Dose: GMC (geometric mean concentration)74.5 (36.9 to 150.4)54.0 (19.0 to 153.8)64.9 (24.4 to 172.8)
PrimaryVP1 Serum Immunoglobin G (IgG) by Mesoscale Discovery (MSD) Assay

Comparison of VPI specific immunoglobin A (IgA) ASC levels by Mesoscale Discovery (MSD) assay between the 3 study cohorts

Time frame:
Day 1 (Initial Vaccination) through Day 29 post boost (Second Vaccination)
Reported as:
Geometric mean · 10^6 AU/mL
VP1 Serum Immunoglobin G (IgG) by Mesoscale Discovery (MSD) Assay
10^6 AU/mLCohort 1 (4-week Boost Vaccination)Cohort 2 (8-week Boost Vaccination)Cohort 3 (12-week Boost Vaccination)
First Dose: GMC (geometric mean concentration)0.5 (0.1 to 2.1)0.3 (0.1 to 1.2)0.2 (0.0 to 1.1)
28-Days post the First Dose: GMC (geometric mean concentration)2.1 (0.9 to 4.9)2.6 (0.8 to 8.7)2.1 (0.4 to 11.2)
28-Days post the Second Dose: GMC (geometric mean concentration)1.5 (0.6 to 3.9)1.2 (0.4 to 3.6)1.7 (0.5 to 6.1)
PrimaryNorovirus G1.1 Histo-blood Group Antigen (HBGA) Blocking Antibodies (BT50) Assay

Comparison of GI.1 histo-blood group antigen (HBGA) blocking antibodies (BT50) levels between the 3 study cohorts

Time frame:
Day 1 (Initial Vaccination) through Day 29 post boost (Second Vaccination)
Reported as:
Geometric mean · Fold Rise
Norovirus G1.1 Histo-blood Group Antigen (HBGA) Blocking Antibodies (BT50) Assay
Fold RiseCohort 1 (4-week Boost Vaccination)Cohort 2 (8-week Boost Vaccination)Cohort 3 (12-week Boost Vaccination)
28-Days post First Dose: GMFR (geometric mean fold rise)1.8 (1.2 to 2.7)2.5 (1.2 to 5.4)2.6 (1.3 to 5.1)
28-Days post Second Dose: GMFR (geometric mean fold rise)2.5 (1.5 to 4.1)2.4 (1.3 to 4.3)3.1 (1.8 to 5.1)
SecondarySolicited Symptoms of Reactogenicity

Comparison of frequency, duration, and severity of solicited symptom events in participants

Time frame:
Day 1 (Vaccination) to Day 8 post each vaccination
Reported as:
Number · events
Solicited Symptoms of Reactogenicity
eventsCohort 1 (4-week Boost Vaccination)Cohort 2 (8-week Boost Vaccination)Cohort 3 (12-week Boost Vaccination)
Fever: Total000
Fever: Mild000
Fever: Moderate000
Headache: Total515
Headache: Mild413
Headache: Moderate102
Myalgia: Total212
Myalgia: Mild202
Myalgi: Moderate010
Abdominal Pain: Total223
Abdominal Pain: Mild212
Abdominal Pain: Moderate011
Anorexia: Total100
Anorexia: Mild100
Anorexia: Moderate000
Nausea: Total102
Nausea: Mild102
Nausea: Moderate000
Vomiting: Total102
Vomiting: Mild102
Vomiting: Moderate000
Diarrhea: Total324
Diarrhea: Mild213
Diarrhea: Moderate111
Malaise/Fatigue: Total313
Malaise/Fatigue: Mild212
Malaise/Fatigue: Moderate101
Other pre-specifiedUnsolicited Adverse Events (AEs)

Comparison of the frequency, duration, and severity of unsolicited AEs and serious AEs (SAEs) including AEs of Special Interest (AESIs) and new onsets of chronic illness (NOCIs) in participants

Time frame:
Day 1 (Vaccine) through 28 days following boost (Second Vaccination)
Reported as:
Number · events
Unsolicited Adverse Events (AEs)
eventsCohort 1 (4-week Boost Vaccination)Cohort 2 (8-week Boost Vaccination)Cohort 3 (12-week Boost Vaccination)
Syncope (Mild)101
Toothache (Mild)001
COVID-19 Pneumonia (Severe)010
Other pre-specifiedLong-term Safety

Frequency, duration, and severity of all SAEs, AESIs and NOCIs through 6 months after last vaccination.

Time frame:
Day 1 (Vaccine) through 6 months following boost (Second Vaccination)

Results for this outcome have not been posted.

PrimaryVP1 Serum Immunoglobin G (IgG) by Mesoscale Discovery (MSD) Assay

Comparison of VPI specific immunoglobin A (IgA) ASC levels by Mesoscale Discovery (MSD) assay between the 3 study cohorts

Time frame:
Day 1 (Initial Vaccination) through Day 29 post boost (Second Vaccination)
Reported as:
Geometric mean · Fold rise
VP1 Serum Immunoglobin G (IgG) by Mesoscale Discovery (MSD) Assay
Fold riseCohort 1 (4-week Boost Vaccination)Cohort 2 (8-week Boost Vaccination)Cohort 3 (12-week Boost Vaccination)
28-Days post the First Dose: GMFR (geometric mean fold rise)4.6 (1.6 to 13.6)8.9 (3.9 to 20.5)11.3 (3.4 to 37.0)
28-Days post the Second Dose: GMFR (geometric mean fold rise)3.3 (1.3 to 8.5)5.4 (2.5 to 11.7)8.9 (2.9 to 26.8)

Adverse events

Collected over 6 months following boost dose. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 (4-week Boost Vaccination)0/10 (0%)0/10 (0%)6/10 (60%)
Cohort 2 (8-week Boost Vaccination)0/10 (0%)1/10 (10%)3/10 (30%)
Cohort 3 (12-week Boost Vaccination)0/10 (0%)0/10 (0%)6/10 (60%)
Most frequent serious events
Most frequent serious events
EventCohort 1 (4-week Boost Vaccination)Cohort 2 (8-week Boost Vaccination)Cohort 3 (12-week Boost Vaccination)
COVID-19 PneumoniaInfections and infestations0/101/100/10
HospitalizationInvestigations0/101/100/10
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCohort 1 (4-week Boost Vaccination)Cohort 2 (8-week Boost Vaccination)Cohort 3 (12-week Boost Vaccination)
HeadacheNervous system disorders5/101/105/10
DiarrheaGastrointestinal disorders3/102/104/10
Abdominal PainGastrointestinal disorders2/102/103/10
FatigueGeneral disorders3/101/103/10
MyalgiaMusculoskeletal and connective tissue disorders2/101/102/10
NauseaGastrointestinal disorders1/100/102/10
VomitingGastrointestinal disorders1/100/102/10
AnorexiaMetabolism and nutrition disorders1/100/100/10
ToothacheGastrointestinal disorders0/100/101/10
SyncopeNervous system disorders1/100/101/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1 (4-week Boost Vaccination)Cohort 2 (8-week Boost Vaccination)Cohort 3 (12-week Boost Vaccination)Total
<=18 years0000
Between 18 and 65 years10101030
>=65 years0000
Age, Continuous
Age, Continuous(years)Cohort 1 (4-week Boost Vaccination)Cohort 2 (8-week Boost Vaccination)Cohort 3 (12-week Boost Vaccination)Total
Mean43.2 ± 7.4235.4 ± 9.9734.9 ± 10.0937.8 ± 9.72
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (4-week Boost Vaccination)Cohort 2 (8-week Boost Vaccination)Cohort 3 (12-week Boost Vaccination)Total
Female47415
Male63615
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 (4-week Boost Vaccination)Cohort 2 (8-week Boost Vaccination)Cohort 3 (12-week Boost Vaccination)Total
Hispanic or Latino3339
Not Hispanic or Latino77721
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 (4-week Boost Vaccination)Cohort 2 (8-week Boost Vaccination)Cohort 3 (12-week Boost Vaccination)Total
American Indian or Alaska Native0000
Asian53311
Native Hawaiian or Other Pacific Islander0000
Black or African American2204
White35715
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Cohort 1 (4-week Boost Vaccination)Cohort 2 (8-week Boost Vaccination)Cohort 3 (12-week Boost Vaccination)Total
United States10101030
Height
Height(centimeter)Cohort 1 (4-week Boost Vaccination)Cohort 2 (8-week Boost Vaccination)Cohort 3 (12-week Boost Vaccination)Total
Mean163.23 ± 7.236175.63 ± 7.850166.22 ± 10.734168.36 ± 10.001
Weight
Weight(kilogram)Cohort 1 (4-week Boost Vaccination)Cohort 2 (8-week Boost Vaccination)Cohort 3 (12-week Boost Vaccination)Total
Mean75.22 ± 9.35986.99 ± 20.45775.54 ± 13.36079.25 ± 15.603

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • WCCT Global, Inc.
    Cypress, California 90630, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Oct 2021, 6 months.

Results were first posted in May 2024, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2021
First posted
May 6, 2021
StartActual
Apr 30, 2021
Primary completionActual
Oct 30, 2021
CompletionActual
Feb 16, 2022
Results first posted
May 22, 2024
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04875676
Lead sponsor
Vaxart
Responsible party
Sponsor
First posted
May 6, 2021
Start date
Apr 30, 2021
Primary completion
Oct 30, 2021
Completion
Feb 16, 2022
Results posted
May 22, 2024
Last update
May 22, 2024

Study contacts

Helen Paguntalan, MD
principal investigator · Icon, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VXA-G1.1-NN

Start the discussion